Orchestra BioMed Holdings (OBIO) Accounts Payables (2020 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Accounts Payables for 7 consecutive years, with $6.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables rose 13.48% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $6.3 million (up 13.48% YoY), while the FY2025 annual figure was $6.1 million, up 18.72% from the prior year.
• Accounts Payables climbed to $6.3 million in Q1 2026 per OBIO's latest filing, from $6.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $8.5 million in Q3 2025 and bottomed at $103607.0 in Q1 2022.
• Historically, Accounts Payables has averaged $4.0 million across 5 years, with a median of $4.0 million in 2022.
• Annual changes were most pronounced in 2022 — Accounts Payables jumped 285778.96% — and 2023, when it decreased 26.92%.
• Orchestra BioMed Holdings' Accounts Payables stood at $4.0 million in 2022, then fell by 26.92% to $2.9 million in 2023, then surged by 77.03% to $5.1 million in 2024, then advanced by 18.72% to $6.1 million in 2025, then climbed by 3.58% to $6.3 million in 2026.
• Business Quant data shows OBIO's Accounts Payables at $6.3 million in Q1 2026, $6.1 million in Q4 2025, and $8.5 million in Q3 2025.